LMICs

CARB-X announced Tuesday an award of up to $3.6 million (plus up to $10.2 million in milestones) to Maryland-based Novel Microdevices to develop a rapid, point-of-care, battery-powered diagnostic for sexually transmitted infections such as chlamydia and gonorrhea.

The test—which will also identify antibiotic resistance—will diagnose infections in about 25 minutes from a vaginal swab or urine sample and require no sample preparation, making it “particularly suited” for LMICs, according…

CARB-X published compulsory guidance on Monday to ensure that new antibacterial products brought to market by its funded companies are used responsibly and made available to people in LMICs.

The Stewardship and Access Plan Development Guide—created by the Boston University-led nonprofit and its partners, including the Access to Medicine Foundation, the Gates Foundation, the Global Antibiotic Research and Development Partnership, the Global Antimicrobial Resistance Innovation Fund, and…

The state of the hunt:

J&J’s single-dose vaccine scored unanimous endorsement from a U.S. FDA advisory committee, clearing the way for a likely EUA.
  The COVAX Facility made its first shipments, sending vaccine doses to Ghana and Ivory Coast.
  Moderna and Pfizer made progress toward clinical trials of modified, variant-specific vaccines.

 

Vaccines


Approved or authorized vaccines
  
Pfizer/BioNTech shot continues strong showing…

Pfizer announced Tuesday the launch of a new partnership with the Netherlands-based IDA Foundation to provide “equitable access to quality cancer treatments” in almost 70 low- and middle-income countries across Latin America, Asia, Africa and the Western Pacific region.

The agreement will allow developing country governments and non-governmental organizations to access 18 essential cancer treatments and 30 formulations from Pfizer’s portfolio, including options for treating breast,…

The state of the hunt:

Regulators in Brazil, Canada and Europe commenced accelerated “rolling reviews” of AstraZeneca’s vaccine candidate even as the U.S. FDA widened its probe of the shot amid safety concerns.
  Serum Institute of India doubled its commitment of affordable Covid-19 vaccine doses to the COVAX AMC, pledging up to 200 million.
  The ACT Accelerator launched a partnership to provide 120 million Covid-19 rapid antigen tests to LMICs over six months.

 …

The UN’s Medicines Patent Pool (MPP) and the World Heart Federation announced Monday that they have signed a memorandum of understanding, pledging to collaborate to pursue wide availability of essential medicines for cardiovascular diseases (CVDs). Citing the high costs of newer drugs, the organizations said in a joint press release that the tie-up “could be a game-changer in access to the most innovative CVD medicines in LMICs.”

In August, MPP—previously focused on infectious…

Serum Institute of India (SII) will double its initial commitment of doses of affordable Covid-19 vaccines for the Gavi-led COVAX Advance Market Commitment (COVAX AMC), the Hyderabad-based company announced yesterday—pledging up to 200 million doses as early as the first half of 2021.

A separate Gavi press release said the $300 million arrangement—funded by the Gates Foundation’s Strategic Investment Fund—provides “an option to secure additional doses, potentially several times the 200…

Novartis today announced a $2.2 billion “sustainability-linked bond” that the company says incentivizes its efforts to reach over 24 million people in low- and middle-income countries (LMICs) by 2025 through its Chagas, leprosy, malaria, and sickle cell disease access programs.

According to a Novartis press release, the Access to Medicine Foundation validated the bond’s targets, which also include a 200% increase in LMIC patients reached with unspecified “strategic innovative therapies…